Danco Laboratories asks Supreme Court to decide abortion pill case

Danco Laboratories asks Supreme Court to decide abortion pill case


U.S. President Joe Biden delivers remarks on abortion rights in a speech hosted by the Democratic National Committee (DNC) at the Howard Theatre in Washington, October 18, 2022.

Leah Millis | Reuters

The drug company Danco Laboratories has asked the Supreme Court to review the case challenging the legality of the abortion pill mifepristone.

Danco’s request comes in response to a ruling by the U.S. Court of Appeals for the 5th Circuit that would impose major restrictions on how the medication is used and distributed to patients.

The drug company has asked the Supreme Court to reverse the lower court ruling, saying the case is of “indisputable importance” to women’s health.

“For the women and teenage girls, health care providers, and States that depend on FDA’s actions to ensure safe and effective reproductive health care is available, this case matters tremendously,” Danco’s attorneys wrote in their filing.

“And for the pharmaceutical and biotechnology industry, permitting judicial second- guessing of FDA’s scientific evaluations of data will have a wildly destabilizing effect,” the attorneys wrote.

The appeals court ruling is on hold until the Supreme Court makes a decision about the case. The high court, in April, pressed pause on lower court decisions as litigation about the pill proceeds in response to a request from the Biden administration.

A three-judge panel at the 5th Circuit ruled that decisions the Food and Drug Administration took in recent years to make mifepristone more accessible to women failed to address safety concerns.

Should the Supreme Court take the case and uphold the appeals court decision, mifepristone will remain on the market in the U.S. but patients will face more barriers to accessing the medication.

If the high court declines to take the case, the appeals court restrictions will go into effect.

Mifepristone, used in combination with another drug called misoprostol, is the most common method to terminate a pregnancy in the U.S.

CNBC Health & Science

Read CNBC’s latest health coverage:

The appeals court order would end mail delivery of mifepristone and prescriptions via telemedicine appointments. Women would have to see a doctor in person to get a prescription and go to three follow-up visits as they take the course of medication.

The ruling also shortens the time when women can take mifepristone to seven weeks into their pregnancy, down from 10 weeks currently.

The litigation against mifepristone began last November when a group of physicians who oppose abortion called the Alliance for Hippocratic Medicine sued to overturn the FDA’s original approval of the pill, which dates back more than 20 years.

U.S. Judge Matthew Kacsmaryk of the U.S. District Court for the Northern District of Texas issued a sweeping order in April that suspended the FDA approval of mifepristone.

The appeals court dialed back Kacsmaryk’s order and kept the original FDA approval in place as well as the agency’s authorization of a generic form of the pill.

This is breaking news. Please check back for updates.



Source

Healthy Returns: What to know about the FDA’s plan to speed up some drug reviews
Health

Healthy Returns: What to know about the FDA’s plan to speed up some drug reviews

FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009.  Jason Reed | Reuters A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. The Food […]

Read More
Taking on Goliath: Brain surgeon’s clash with UnitedHealthcare shows insurer’s hardball tactics
Health

Taking on Goliath: Brain surgeon’s clash with UnitedHealthcare shows insurer’s hardball tactics

Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice she says is in serious jeopardy because of recent moves by UnitedHealth Group. Zach Gross for NBC News Dr. Catherine Mazzola, a pediatric neurosurgeon, runs a practice in New Jersey that treats low-income children on Medicaid. Since 2008, she has cared for boys and girls with cerebral palsy, […]

Read More
FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option
Health

FDA approves Gilead’s twice-yearly HIV prevention injection, offering a powerful and convenient new option

The logo of Gilead Sciences pharmaceutical company is seen in Oceanside, California, April 29, 2020. Mike Blake | Reuters The Food and Drug Administration on Wednesday approved Gilead’s twice-yearly antiviral injection for preventing HIV – a milestone that the company and some experts say could help bring the world closer to ending the decades-long epidemic […]

Read More